Patents by Inventor Pierre van der Bruggen

Pierre van der Bruggen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof
    Patent number: 5591430
    Abstract: Tumor rejection antigens derived from tumor rejection precursor MAGE-3 have been identified. These "TRAS" bind to the MHC-class I molecule HLA-A2, and the resulting complexes stimulate the production of cytolytic T cell clones which lyse the presenting cells. The peptides and complexes may be used diagnostically, therapeutically, and as immunogens for the production of antibodies, or as targets for the generation of cytolytic T cell clones.
    Type: Grant
    Filed: June 17, 1994
    Date of Patent: January 7, 1997
    Assignees: Ludwig Institute for Cancer Research, The Chancellor, Masters and Scholars of the University of Oxford
    Inventors: Alan Townsend, Judy Bastin, Thierry Boon-Falleur, Pierre van der Bruggen, Pierre Coulie, Thomas Gajewski
  • Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof
    Patent number: 5585461
    Abstract: Tumor rejection antigens derived from tumor rejection precursor MAGE-3 have been identified. These "TRAS" bind to the MHC-class I molecule HLA-A2, and the resulting complexes stimulate the production of cytolytic T cell clones which lyse the presenting cells. The peptides and complexes may be used diagnostically, therapeutically, and as immunogens for the production of antibodies, or as targets for the generation of cytolytic T cell clones.
    Type: Grant
    Filed: March 24, 1994
    Date of Patent: December 17, 1996
    Assignees: Ludwig Institute for Cancer Research, The Chancellor, Masters and Scholars of the University of Oxford
    Inventors: Alan Townsend, Judy Bastin, Thierry Boon-Falleur, Pierre van der Bruggen, Pierre Coulie
  • Isolated nucleic acid molecules coding for BAGE tumor rejection antigen precursors
    Patent number: 5571711
    Abstract: A new family of tumor rejection antigen precursors, and the nucleic acid molecules which code for them, are disclosed. These tumor rejection antigen precursors are referred to as BAGE tumor rejection antigen precursors, and the nucleic acid molecules which code for them are referred to as BAGE coding molecules. Various diagnostic and therapeutic uses of the coding sequences and the tumor rejection antigen precursor molecules are described.
    Type: Grant
    Filed: June 17, 1993
    Date of Patent: November 5, 1996
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Pierre van der Bruggen, Thierry Boon-Falleur, Pierre Coulie, Jean-Christophe Renauld
  • Peptides which are derived from tumor rejection antigen precursor molecule MAGE-1, which complex to MHC molecule HLA-C clone 10, and uses thereof
    Patent number: 5558995
    Abstract: The invention relates to the identification of complexes of HLA-C-clone 10 and MAGE-1 derived peptides on the surfaces of abnormal cells. The therapeutic and diagnostic ramifications of this observation are the subject of the invention.
    Type: Grant
    Filed: February 14, 1994
    Date of Patent: September 24, 1996
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Pierre van der Bruggen, Thierry Boon-Falleur
  • Isolated tumor rejection antigen precursor MAGE-2 derived peptides, and uses thereof
    Patent number: 5554724
    Abstract: The invention describes peptides derived from tumor rejection antigen precursor MAGE-2. These peptides bind with HLA-A2 molecules, thus presenting complexes which provoke cytolytic T cell production. The resulting "CTLs" are specific for complexes of HLA-A2 and the peptide. The complexes can be used to generate monoclonal antibodies. The cytolytic T cells produced may be used in the context of immunotherapy, such as adoptive transfer.
    Type: Grant
    Filed: March 24, 1994
    Date of Patent: September 10, 1996
    Assignee: University of Leiden
    Inventors: Cornelis J. M. Melief, M. J. W. Visseren, W. M. Kast, Pierre van der Bruggen, Thierry Boon-Falleur
  • Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof
    Patent number: 5554506
    Abstract: Tumor rejection antigens derived from tumor rejection precursor MAGE-3 have been identified. These "TRAS" bind to the MHC-class I molecule HLA-A2, and the resulting complexes stimulate the production of cytolytic T cell clones which lyse the presenting cells. The peptides and complexes may be used diagnostically, therapeutically, and as immunogens for the production of antibodies, or as targets for the generation of cytolytic T cell clones.
    Type: Grant
    Filed: March 24, 1994
    Date of Patent: September 10, 1996
    Assignee: Ludwig Institute For Cancer Research
    Inventors: Pierre van der Bruggen, Thierry Boon-Falleur, Catia Traversari, Katharina Fleischauer
  • Monoclonal antibodies which bind to tumor rejection antigen precursor mage-1
    Patent number: 5541104
    Abstract: The invention relates to monoclonal antibodies which specifically bind to the tumor rejection antigen precursor molecule MAGE-1, hybridomas which produce these monoclonal antibodies, and their use. Also described is a recombinant form of MAGE-1, peptides which are useful as immunogens, and immunogenic compositions containing the peptides and an adjuvant.
    Type: Grant
    Filed: February 1, 1994
    Date of Patent: July 30, 1996
    Assignees: Ludwig Institute for Cancer Research, Cornell Research Foundation, Inc.
    Inventors: Yao-Tseng Chen, Elisabeth Stockert, Yachi Chen, Pilar Garin-Chesa, Wolfgang J. Rettig, Pierre van der Bruggen, Thierry Boon-Falleur, Lloyd J. Old
  • Method for determining head and neck squamous cell carcinomas, prostate carcinomas, and bladder tumors by assaying for mage-3
    Patent number: 5512437
    Abstract: A method for determining head and neck squamous cell carcinomas, bladder tumors and prostate carcinomas is described. The method involves assaying for expression of the gene coding for tumor rejection antigen precursor MAGE-3, or its expression product. Various assays, and kits useful for these assays, are described.
    Type: Grant
    Filed: March 1, 1994
    Date of Patent: April 30, 1996
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Beatrice Gaugler, Thierry Boon-Falleur, Benoit van den Eynde, Etienne DePlaen, Francis Basseur, Bernard Lethe, Pierre van der Bruggen
  • Isolated nucleic acid molecules which encode MAGE derived nonapeptides
    Patent number: 5462871
    Abstract: The invention relates to isolated nucleic acid molecules which encode nonapeptides derived from MAGE tumor rejection antigen precursors. The nonapeptides form complexes with human leukocyte antigens presented on the surfaces of cells, and lead to lysis of these cells by cytolytic T lymphocytes. Thus, they are useful in diagnostic methods. Also a part of the invention are vectors which are designed to encode the nonapeptides as well as cell lines which have been transformed or transfected with the isolated nucleic acid molecules of the invention, or vectors including these molecules.
    Type: Grant
    Filed: June 7, 1993
    Date of Patent: October 31, 1995
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Thierry Boon-Falleur, Pierre van der Bruggen, Etienne De Plaen, Christophe Lurquin, Catia Traversari, Beatrice Gaugler, Benoit Van den Eynde
  • Isolated nonapeptides derived from MAGE genes and uses thereof
    Patent number: 5405940
    Abstract: The invention involves the reception of particular nonapeptides by HLA molecules. The nonapeptides are derived from expression products of the MAGE gene family. The resulting complexes are identified by cytolytic T cells. Such recognition may be used in diagnostics, or therapeutically.
    Type: Grant
    Filed: August 31, 1992
    Date of Patent: April 11, 1995
    Assignee: Ludwig Institute For Cancer Research
    Inventors: Thierry Boon, Pierre van der Bruggen, Etienne De Plaen, Christophe Lurquin, Catia Traversari
  • Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
    Patent number: 5342774
    Abstract: The invention relates to an isolated DNA sequence which codes for an antigen expressed by tumor cells which is recognized by cytotoxic T cells, leading to lysis of the tumor which expresses it. Also described are cells transfected by the DNA sequence, and various therapeutic and diagnostic uses arising out of the properties of the DNA and the antigen for which it codes.
    Type: Grant
    Filed: December 12, 1991
    Date of Patent: August 30, 1994
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Thierry Boon, Pierre van der Bruggen, Benoit Van den Eynde, Aline Van Pel, Etienne De Plaen, Christophe Lurquin, Patrick Chomez, Catia Traversari